Withdrawal symptoms predict prescription opioid dependence in chronic pain patients

Coloma-Carmona, Ainhoa; Carballo, José Luís; Marín, Jesús Rodríguez; Pérez-Carbonell, Ana

doi:10.1016/j.drugalcdep.2018.11.013

Cited by 21 publications

(16 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that taking crocin for 12 weeks by patients under MMT improved craving and withdrawal symptoms; however, it did not have any effect on cognitive function. Previous evidence has shown that craving, withdrawal symptoms, and cognitive disturbances were present in opioid use disorder (Coloma‐Carmona et al, 2019; Kakko et al, 2019; Mazhari et al, 2015). Crocin did not indicate any major adverse effect during the trial.…”

Section: Discussionmentioning

confidence: 96%

“…Although doing several practical implementation of MMT, various challenges and questions remained unclear. Withdrawal syndrome, craving, and cognitive deficits are common among the opioid abusers treated with MMT (Coloma‐Carmona, Carballo, Rodríguez‐Marín, & Pérez‐Carbonell, 2019; Kakko et al, 2019; Mazhari, Keshvari, Sabahi, & Mottaghian, 2015), which affect on their quality of life and increasing the risk of substance relapse.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of crocin (the main active saffron constituent) on the cognitive functions, craving, and withdrawal syndrome in opioid patients under methadone maintenance treatment

Abbaszadeh-Mashkani

Hoque

Banafshe

et al. 2020

Phytotherapy Research

View full text Add to dashboard Cite

Individuals under methadone maintenance treatment (MMT) programs are susceptible to several complications, including withdrawal syndrome, craving, and cognitive deficits. This study was designed to elevate the effect of crocin administration on withdrawal syndrome, craving, and cognitive function in subjects under MMT programs. It was a clinical trial that was conducted among 60 patients referred to Soltan Mirahmad Clinic for addict patients in Kashan, Iran. The patients were allocated to two groups including placebo and intervention groups. The intervention group received 30 mg/day crocin (n = 30) and placebo (n = 30) once a day, in 12 weeks. Withdrawal syndrome, craving, and cognitive function parameters were measured before and after the intervention in subjects under MMT programs. Compared with the placebo group, crocin resulted in a significant improvement in craving score (p = .03), and withdrawal symptoms score (p = .01) in the intervention group. In addition, crocin supplementation did not affect cognitive function parameters (e.g., TMT, FAS test, and DGSP score). Overall, crocin supplementation for 12 weeks to patients under MMT programs had beneficial effects on craving and withdrawal symptoms score, but did not affect the cognitive function parameters.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

The effect of crocin (the main active saffron constituent) on the cognitive functions, craving, and withdrawal syndrome in opioid patients under methadone maintenance treatment

Abbaszadeh-Mashkani

Hoque

Banafshe

et al. 2020

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…We are confused about what to call prescription opioid dependence, worried about using the word addiction, and bound by diagnostic coding that constrains our treatment choices but often does not fit the patients we see. This confusion, combined with the failure to recognize that the brain adapts similarly during longterm medical and non-medical opioid use, 35 reinforces the idea that medical use is always good, and nonmedical use is always bad.…”

Section: Opioid Dependencementioning

confidence: 93%

When Physical and Social Pain Coexist: Insights Into Opioid Therapy

Sullivan

Ballantyne

2020

Ann Fam Med

View full text Add to dashboard Cite

“…14 The search yielded a total of 784 potentially relevant papers after duplicates exclusion. Later, 703 were excluded based on examination of titles and abstracts, leaving 81 for full-text analysis; finally, 62 articles were excluded by this analysis, and a total of 19 articles (involving 55,647 patients) 4,5,8,11,[15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] were included in the qualitative and quantitative synthesis.…”

Section: Study Selectionmentioning

confidence: 99%

“…The included studies were published between 2002 4 and 2019 17 and were carried out mostly in the United States 4,5,8,11,[15][16][17]20,21,[23][24][25][26][27][28][29] with three exceptions, which were conducted in Spain, 18 Germany, 22 and Israel. 19 The most common designs were cross-sectional (n = 13), 11,[16][17][18][19][20][22][23][24][25][26]28,29 followed by retrospective cohort (n = 4), 4,5,8,15 one prospective cohort (n = 1), 21 and one clinical trial (n = 1). 27 The method used to identify POU was mostly questionnaires: two used telephone questionnaires, 15,16 six used a face-to-face interview, 11,17,18,20,21,23 and seven used a self-completed questionnaire with help available from an interviewer (if required).…”

Section: Characteristics Of Selected Studiesmentioning

confidence: 99%

Prevalence of Problematic Use of Opioids in Patients with Chronic Noncancer Pain: A Systematic Review with Meta‐analysis

2021

View full text Add to dashboard Cite

Background and Objective: Opioid prescription for chronic noncancer pain is associated with problematic use. We aimed to review and summarize the evidence on the prevalence of problematic use of opioids in adults with chronic noncancer pain and investigate whether the prevalence rates were changing over time. Databases and Data Treatment: A systematic review of the literature was undertaken following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We systematically searched the literature in the electronic databases MEDLINE, SCOPUS, and Web of Science and studies with adult participants with chronic noncancer pain using opioids with indication of one or more of the following terms about problematic opioid use: abuse, misuse, addiction, dependence, problematic use, and aberrant behavior/use were eligible for data extraction. Meta-analysis was performed to estimate the pooled prevalence rates using a random-effects model, and subanalysis was conducted. Results: Our search identified a total of 784 potentially relevant studies. After a thorough evaluation, 19 papers, mostly from the United States, were included in our qualitative and quantitative synthesis. The majority of the data came from speciality pain clinics. The estimated prevalence of problematic use of opioids in adults with chronic noncancer pain was 36.3% (95% confidence interval: 27.4 to 45.2%; I 2 = 99.64%). Problematic opioid use was mostly identified using the questionnaire method. Thirteen studies (68%) presented a low risk of bias. Conclusions: Our study presents an alarming estimate regarding the prevalence of problematic use of opioids among patients with noncancer pain. These results deserve special attention from health care professionals and health authorities. &

show abstract

Withdrawal symptoms predict prescription opioid dependence in chronic pain patients

Cited by 21 publications

References 46 publications

The effect of crocin (the main active saffron constituent) on the cognitive functions, craving, and withdrawal syndrome in opioid patients under methadone maintenance treatment

The effect of crocin (the main active saffron constituent) on the cognitive functions, craving, and withdrawal syndrome in opioid patients under methadone maintenance treatment

When Physical and Social Pain Coexist: Insights Into Opioid Therapy

Prevalence of Problematic Use of Opioids in Patients with Chronic Noncancer Pain: A Systematic Review with Meta‐analysis

Contact Info

Product

Resources

About